Shear wave elastography imaging for assessing the chronic pathologic changes in advanced diabetic kidney disease

Objective: The assessment of the grade of renal fibrosis in diabetic kidney disease (DKD) requires renal biopsy, which may be associated with certain risks. To assess the severity of chronic pathologic changes in DKD, we performed a quantitative analysis of renal parenchymal stiffness in advanced DKD, using shear wave elastography (SWE) imaging.

Patients and methods: Twenty-nine diabetic patients with chronic kidney disease (CKD) grades 3–4 due to DKD, and 23 healthy subjects were enrolled. Combined conventional ultrasound and SWE imaging were performed on all participants. The length, width, and cortical thickness and stiffness were recorded for each kidney.

Results: Cortical thickness was lower in patients with DKD than in healthy subjects (13.8±2.2 vs 14.8±1.6 mm; P=0.002) and in DKD patients with CKD grade 4 than in those with grade 3 (13.0±3.5 vs 14.7±2.1 mm; P<0.001). Cortical stiffness was greater in patients with DKD than in healthy subjects (23.7±14.33 vs 9.02±2.42 kPa; P<0.001), in DKD patients with CKD grade 4 than in those with grade 3 (30.4±16.2 vs 14.6±8.1 kPa; P<0.001), and in DKD patients with CKD grade 3b, than in those with CKD grade 3a (15.7±6.7 vs 11.0±4.2 kPa; P=0.03). Daily proteinuria was higher in DKD patients with CKD grade 4 than in those with grade 3 (5.5±0.96 vs 1.13±0.72; P<0.001), and in DKD patients with CKD grade 3b, than in those with CKD grade 3a (1.59±0.59 vs 0.77±0.48; P<0.001). Cortical stiffness was inversely correlated with the estimated glomerular filtration rate (r=-0.65, P<0.001) and with cortical thickness (r=-0.43, P<0.001) in patients with DKD.

Conclusions: In patients with advanced DKD, SWE imaging may be utilized as a simple and practical method for quantitative evaluation of the chronic morphologic changes and for the differentiation between CKD grades.

Keywords: diabetic kidney disease, shear wave, elastography, cortical stiffness

Introduction

Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide. Clinically, diabetic kidney disease (DKD) is characterized by a progressive increase in proteinuria, a decline in glomerular filtration rate (GFR), elevated blood pressure, and a high risk of kidney failure. In addition, advanced DKD is characterized by morphologic renal changes that include varying degrees of fibrosis.1,2

For a number of decades, the evaluation of renal disorders has been based on a variety of conventional methods, including ultrasound, computerized tomography, magnetic fields, and biochemical analysis. Although the progression of DKD can be assessed from routine biochemical tests, such as the amount of urinary protein and serum creatinine levels, assessment of the grade of renal fibrosis requires renal biopsy.
This is an invasive and costly procedure that may be associated with certain risks and is not routinely performed.\(^3\)–\(^5\)

While kidney biopsy is required for the definitive diagnosis of diabetic nephropathy, in most cases, careful screening of diabetic patients can identify people with DKD without the need for kidney biopsy. Thus, renal biopsy is usually considered when the course of DKD is not typical, as when other diseases, such as membranous nephropathy, are suspected. Although most complications of renal biopsies are mild and resolve spontaneously, major complications have been reported in up to 7.3% of biopsies.\(^3\) Renal insufficiency is considered a main risk factor for the development of complications after renal biopsies. The risk of bleeding has been shown to increase with worsening of the degree of renal insufficiency.\(^4\) Compared to patients with normal renal function, patients with CKD grades 3 and 4 have a six-fold increased risk of severe bleeding.\(^4\) Despite the identification of predisposing risk factors, there is no definitive way to predict which patients will develop serious bleeding. Therefore, a noninvasive method may be preferred for assessing the severity and progression of chronic renal changes, particularly in cases in which it is advisable to avoid performing a kidney biopsy, such as in DKD patients with a single kidney or in those who are receiving anticoagulant therapy. Thus, shear wave elastography (SWE) imaging may be applied as a simple tool for assessing the severity of chronic morphologic changes and for establishing categories of severity based on cortical stiffness measurements, at least in cases in which renal biopsy should be avoided or is contraindicated. Certainly, other studies are needed to establish the correlations between cortical stiffness, morphologic changes, and renal function.

Conventional renal ultrasound may reveal reduced renal length and cortical thickness, as well as increased cortical echogenicity, which may suggest the presence of chronic atrophic morphological changes in a variety of renal diseases. However, these measurements are not quantitative. Moreover, in diabetic patients, kidneys frequently do not show atrophic changes by conventional renal ultrasound, even in advanced DKD with CKD grades 3 and 4. Therefore, conventional renal ultrasound is, generally, not informative for the evaluation of the progression of DKD and not useful for the differentiation between the CKD grades.\(^1,\)\(^2,\)\(^6\)

SWE imaging, based on acoustic radiation force impulse (ARFI) technology, is a noninvasive and cost effective ultrasound diagnostic method that has been developed for the evaluation of tissue elasticity.\(^7\)–\(^10\) Essentially, SWE technology measures the velocity of the shear wave (in m/s) that passes through the examined tissue, and then converts this measurement into a tissue stiffness measurement that is expressed in kPa.\(^7\)–\(^11\) Combined conventional and SWE imaging can provide qualitative and quantitative assessments of tissue elasticity. A number of recent applications of SWE have focused on the evaluation of the mechanical properties of renal tissue.\(^7\)–\(^11\)

Mechanical properties of the kidney depend on its histology, particularly the amount of fibrosis in the renal parenchyma. A simple, practical, and noninvasive measure is needed for quantitative assessment of renal fibrosis. Yet, the ARFI technique is difficult to apply to native kidneys because of the limited detection depth, which is a maximum of 8 cm from the probe surface. Only a few studies examined renal elastographic parameters in native kidneys of patients with DKD. Goya et al\(^10\) and Yu et al\(^11\) showed that ARFI can be used to assess renal morphologic changes in patients with DKD. Goya et al\(^10\) evaluated the changes in the elasticity of the renal parenchyma in healthy volunteers and patients with diabetic nephropathy using ARFI imaging. The shear wave velocities (m/s) for the kidneys were higher in patients with stage 1–5 diabetic nephropathy than healthy volunteers, and it was concluded that ARFI imaging was able to distinguish between different diabetic nephropathy stages (except for stage 5). Also, Yu et al\(^11\) evaluated the changes in the elasticity of the renal parenchyma in healthy volunteers and three groups of patients with diabetic nephropathy, according to their urinary albumin-to-creatinine ratio (ACR): normoalbuminuria (ACR <30 mg/g), microalbuminuria (ACR 30–300 mg/g), and macroalbuminuria (ACR ≥300 mg/g and estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73 m\(^2\)), to determine and to compare the shear wave velocity of the renal cortex between these groups.\(^6\) The results showed that there was no significant difference between the normoalbuminuria and healthy subjects, but there was a significant difference between the microalbuminuria and macroalbuminuria groups and the healthy subjects. It was concluded that it is feasible to use ARFI imaging to determine the renal cortical shear wave velocity for judging renal injury in type 2 diabetes mellitus.

In the current study, we investigated whether renal SWE imaging expressed in kPa can serve as a practical and noninvasive tool for quantitative assessment of renal fibrosis in DKD patients with CKD grades 3a, 3b, and 4, where conventional renal ultrasound is not informative for the evaluation of the progression of DKD and not useful for the differentiation between CKD grades.
Materials and methods

The study protocol was approved by the Institutional Helsinki Committee of Galilee Medical Center, Naharia, Israel (no 0096-14-NHR) and written informed consent was obtained from all participants.

Twenty-nine patients with type 2 diabetes mellitus and CKD grade 3–4 due to DKD, and 23 healthy subjects were enrolled in the study. All patients with DKD were receiving diabetic treatment, seven (24.1%) were receiving oral antidiabetic treatment, and 22 (75.9%) were receiving insulin therapy. The eGFR was calculated by using the CKD epidemiology collaboration (CKD-EPI) equation:

\[
\text{GFR} = 141 \times \min\left(\frac{\text{Scr}}{\kappa}, 1\right) \times \alpha \times \max\left(\frac{\text{Scr}}{\kappa}, 1\right) - 1.209 \times 0.993^{\text{Age}} \times 1.018 \times \left[1 + \frac{0.329}{\text{if female}} + 0.580 \times \text{if African ethnicity}\right] 
\]

where Scr is serum creatinine (mg/dL); \(\kappa\) is 0.7 for females, and 0.9 for males; \(\alpha\) is \(-0.329\) for females and \(-0.411\) for males; \(\min\) indicates the minimum of \(\text{Scr}/\kappa\) or 1; and \(\max\) indicates the maximum of \(\text{Scr}/\kappa\) or 1.\(^2\) Daily urinary protein excretion was determined by 24-hour urine collection. Diabetic nephropathy was defined on the basis of a urinary albumin excretion of more than 300 mg in a 24-hour urine collection. The study group comprised 29 patients with DKD: 14 with CKD grade 3 and 15 with CKD grade 4. Their mean eGFR was 32.0±11.6 mL/min/1.73 m\(^2\) and mean daily proteinuria level was 1.61±1.09 g/day. Characteristics of the study population are summarized in Table 1.

Statistical methods

Statistical analysis was carried out using Statistical Package for the Social Sciences (SPSS) (IBM SPSS Statistics Version 21, Armonk, NY, USA) software; \(P<0.05\) was considered to be significant. Continuous variables were reported as mean values and standard deviations, and categorical variables as frequencies and percentages. The unpaired \(t\)-test was used to compare the differences between the study groups, according to age, BMI, HbA1c, eGFR, proteinuria level, kidney length, kidney width, cortical thickness, and cortical stiffness. The Chi square test was used to compare the gender distribution between the study groups. Pearson’s correlation coefficient test was used to describe associations between cortical stiffness, age, eGFR, and cortical thickness.

Results

The study group comprised 29 patients with DKD: 14 with CKD grade 3 and 15 with CKD grade 4. Their mean eGFR was 32.0±11.6 mL/min/1.73 m\(^2\) and mean daily proteinuria level was 1.61±1.09 g/day. Characteristics of the study population are summarized in Table 1.

Cortical thickness was significantly lower in patients with DKD than in healthy subjects (13.8±2.2 vs 14.8±1.6 mm; \(P=0.002\)) (Table 2) and in DKD patients with CKD grade 4 than in those with grade 3 (13.0±3.5 vs 14.7±2.1 mm; \(P<0.001\)) (Table 3). Stratifying by gender, cortical thickness
# Demographic and laboratory characteristics of the study population

<table>
<thead>
<tr>
<th>Variables</th>
<th>DKD patients with CKD grades 3 and 4</th>
<th>Healthy subjects</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>29</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>17 (58.6)</td>
<td>13 (56.5)</td>
<td>0.525</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>12 (41.4)</td>
<td>10 (43.5)</td>
<td>0.997</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.12±10.85</td>
<td>58.50±9.420</td>
<td>0.099</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.46±2.85</td>
<td>26.86±2.00</td>
<td>0.044</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.32±0.43</td>
<td>5.48±0.32</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Proteinuria (g/day)</td>
<td>1.61±1.09</td>
<td>≤0.15</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus, n</td>
<td>29</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Oral antidiabetic therapy, n (%)</td>
<td>7 (24.1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Insulin therapy, n (%)</td>
<td>22 (75.9)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>ACEIs or ARBs</td>
<td>18 (62.1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>DKD and CKD grade 3, n</td>
<td>14</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>DKD and CKD grade 4, n</td>
<td>15</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Values of age, BMI, HbA1c, eGFR, and daily proteinuria are represented as mean ± standard deviation.

**Abbreviations:** CKD, chronic kidney disease; DKD, diabetic kidney disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II blockers.

# Conventional and shear wave elastography imaging parameters

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with CKD grade 3–4 due to DKD</th>
<th>Healthy subjects</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>29</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Number of evaluated kidneys</td>
<td>58</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Kidney length (cm)</td>
<td>10.60±1.14</td>
<td>10.49±0.91</td>
<td>0.289</td>
</tr>
<tr>
<td>Kidney width (cm)</td>
<td>4.79±0.66</td>
<td>4.67±0.53</td>
<td>0.138</td>
</tr>
<tr>
<td>Cortical thickness (mm) (all patients)</td>
<td>13.8±2.2</td>
<td>14.8±1.6</td>
<td>0.002</td>
</tr>
<tr>
<td>Cortical thickness (mm) (males)</td>
<td>14.0±1.32</td>
<td>14.9±1.7</td>
<td>0.002</td>
</tr>
<tr>
<td>Cortical thickness (mm) (females)</td>
<td>13.3±1.2</td>
<td>14.7±1.2</td>
<td>0.002</td>
</tr>
<tr>
<td>Cortical stiffness (kPa) (all patients)</td>
<td>23.7±14.33</td>
<td>9.02±2.42</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortical stiffness (kPa) (males)</td>
<td>24.3±17.21</td>
<td>9.63±2.49**</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortical stiffness (kPa) (females)</td>
<td>22.89±9.58</td>
<td>8.73±2.46**</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Notes:** Values are presented as mean ± standard deviation. *P=0.078; **P=0.05; ***P=0.353; ****P=0.117.

**Abbreviations:** CKD, chronic kidney disease; DKD, diabetic kidney disease.

# Shear wave elastography imaging parameters in CKD grade 3 and grade 4 due to DKD

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with CKD grade 3a due to DKD</th>
<th>Patients with CKD grade 3b due to DKD</th>
<th>P-value*</th>
<th>Patients with CKD grade 3 due to DKD</th>
<th>Patients with CKD grade 4 due to DKD</th>
<th>P-value#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>7</td>
<td>7</td>
<td>14</td>
<td>14</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Number of evaluated kidneys</td>
<td>14</td>
<td>14</td>
<td>28</td>
<td>28</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²)</td>
<td>49.1±4.4</td>
<td>34.9±3.7</td>
<td>&lt;0.001</td>
<td>42.0±8.3</td>
<td>21.7±14.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortical thickness (mm)</td>
<td>14.9±2.1</td>
<td>14.3±2.5</td>
<td>0.496</td>
<td>14.7±2.1</td>
<td>13.0±3.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortical stiffness (kPa)</td>
<td>11.0±4.2</td>
<td>15.7±6.7</td>
<td>0.03</td>
<td>14.6±8.1</td>
<td>30.4±16.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Proteinuria (g/day)</td>
<td>0.77±0.48</td>
<td>1.59±0.59</td>
<td>&lt;0.001</td>
<td>1.13±0.72</td>
<td>5.52±0.96</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Notes:** Values are presented as mean ± standard deviation. *P<; significance between grade 3a and grade 3b variables; **P<; significance between grade 3 and grade 4 variables.

**Abbreviations:** CKD, chronic kidney disease; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate.
was lower for individuals with DKD than for healthy subjects (males: 14.0±1.3 vs 14.9±1.7 mm; P=0.002; females: 13.3±1.2 vs 14.7±1.2 cm; P=0.002). Mean values of cortical thickness were similar in males and females among the diabetic patients, as well as among the healthy subjects (Table 2).

Cortical stiffness was significantly greater in patients with DKD than in healthy subjects (23.72±14.33 vs 9.02±2.42 kPa; P<0.001) (Table 2), in DKD patients with CKD grade 4 than in those with grade 3 (30.4±16.2 vs 14.6±8.1 kPa; P<0.001) (Table 3), and in DKD patients with CKD grade 3b than in those with CKD grade 3a (15.7±6.7 vs 11.0±4.2 kPa; P=0.03) (Table 3). Stratifying by gender, cortical stiffness was greater for individuals with DKD than for healthy subjects: (males: 24.34±17.21 vs 9.63±2.49 kPa; P<0.001; females: 22.89±9.58 vs 8.73±2.46 kPa; P<0.001) (Table 2). Mean values of cortical stiffness were similar in males and females among the diabetic patients, as well as among the healthy subjects (Table 2).

Daily proteinuria was higher in DKD patients with CKD grade 4 than in those with grade 3 (5.52±0.96 vs 1.13±0.72; P=0.001) and in DKD patients with CKD grade 3b than in those with CKD grade 3a (1.59±0.59 vs 0.77±0.48; P<0.001) (Table 3).

Cortical stiffness was inversely correlated with the eGFR (r=-0.65, P<0.001) (Figure 1) and with cortical thickness (r=-0.43, P<0.001) in patients with DKD (Figure 2). Cortical stiffness was positively correlated with daily proteinuria (r=0.56, P<0.001) (Figure 3). Daily proteinuria was inversely correlated with the eGFR (r=-0.53, P<0.001) (Figure 4).

In analysis of the total sample, no correlations were found between cortical stiffness and kidney length, kidney width, and gender. No correlation was found between cortical stiffness and cortical thickness in healthy subjects.

Discussion
Compared to healthy individuals, cortical stiffness was significantly higher and inversely correlated with the eGFR in DKD patients with CKD grades 3 and 4. Moreover, cortical stiffness was significantly higher in DKD patients with CKD grade 3b than in those with CKD grade 3a. These data suggest that SWE may be applied as a noninvasive, simple, cost effective, and reliable imaging technique that can quantitatively assess the extent of cortical fibrosis in advanced DKD, and enable differentiation between CKD grades 3a, 3b, and 4. In contrast, conventional ultrasound and other expensive imaging methods, including computerized tomography and magnetic fields, are not quantitative for the assessment of the severity of chronic morphologic changes, and not informative for differentiation between these CKD grades.

According to Kidney Disease Improving Global Outcomes (KDIGO), classification of CKD is based on the degree of decline in GFR and the presence of...
kidney damage markers, rather than on direct examination of kidney tissue. These markers include abnormalities in urinary protein excretion, urine sediment, electrolyte and solutes, pathologic changes in kidney tissue obtained by biopsy, imaging abnormalities, and history of kidney transplantation. The quantitative information obtained by SWE imaging enables more accurate assessment of the chronic morphological changes associated with the progression of DKD. Furthermore, SWE imaging may be used as a noninvasive, practical, and quantitative kidney damage marker, and as a tool for assigning CKD grades in DKD patients.

While only few studies have documented the use of SWE imaging in relation to native kidneys, SWE has become a useful and practical method to evaluate other organs. For example, although liver biopsy has long been the gold standard procedure for assessing the degree of chronic morphologic changes in the liver, SWE has been used to stage liver fibrosis. Moreover, SWE imaging has been used for the evaluation of pathologic processes in several tissues, including breast, prostate, pancreas, testis, thyroid, and transplanted kidneys. Human native kidneys are located at a greater depth than the liver and transplanted kidneys and, therefore, assessment of their renal elasticity is more difficult. Consequently, the earliest studies of renal SWE imaging were performed in animals and transplanted kidneys. Animal studies on rats and rabbits showed a direct correlation between renal cortical stiffness and renal fibrotic changes, and between an increase in cortical stiffness and a decline in renal function. In studies of transplanted kidneys, increased renal stiffness was detected in cases of transplant rejection and in patients who developed acute deterioration in renal function.

Of the few studies that examined the use of SWE to assess renal stiffness, and its relationship to native kidney function, four evaluated renal elasticity in CKD patients. Only two studies showed that SWE imaging, using ARFI-based technology, can be used to assess renal morphologic changes in patients with DKD. In both studies, histological samples were lacking because renal biopsies were not performed and the diagnosis of DKD was based on the presence of albuminuria and/or reduced kidney function. One study evaluated the elasticity of renal parenchyma in different grades of DKD. The second study evaluated the elasticity of the renal parenchyma in healthy controls and in patients with DKD and different levels of proteinuria. The results of both studies suggest that SWE imaging, using ARFI-based technology, may distinguish between renal elasticity changes in DKD. The results of the present study revealed that SWE imaging can differentiate not only between CKD grades in DKD (as was shown by Goya et al) but also between CKD subgrades 3a, 3b, as was shown for the first time in the present study. Furthermore, the results showed that the cortical stiffness was inversely correlated with the eGFR and positively with the level of proteinuria which, itself, was found to be positively correlated with cortical stiffness. Thus, these data suggest that SWE imaging can be considered as an additional noninvasive and more accurate tool for the evaluation of the severity of chronic morphological changes than other imaging methods, and can contribute to better follow-up regarding the progression of DKD.

Although current treatments that focus on controlling hyperglycemia and hypertension with renin–angiotensin system inhibitors reduce the risk of progressive kidney disease, DKD remains the leading cause of ESRD. Metabolic abnormalities including high levels of glucose and lipids may produce glycated lipids and reactive oxygen species that lead to the production of inflammatory cytokines and profibrotic factors. These may incur mesangial, endothelial, and epithelial damage that ultimately results in the development of glomerulosclerosis and tubulointerstitial fibrosis that are characteristic of DKD. Based on these advances, novel therapeutic agents, targeting different mechanisms of DKD, are under evaluation. Renal biopsies are not practical for following the response to such agents. In contrast, renal SWE imaging may be considered a reliable and alternative method for providing additional information concerning the severity and progression of the chronic changes of DKD and the therapeutic response to the investigational therapies.
In summary, while kidney biopsy remains the gold standard for diagnosing renal chronic morphological changes, this method is an invasive and expensive procedure that requires hospitalization, and may be associated with various risks. Renal insufficiency predisposes to dangerous complications after renal biopsies, particularly severe bleeding. Additionally, sometimes biopsies should be repeated periodically to monitor disease progression. Although the idea of a noninvasive method to detect the progression of CKD in the diabetic patient is tempting, the actual need for renal biopsy in diabetics is restricted to certain medical situations, such as the presence of hematuria, active sediments, heavy proteinuria, or an atypical course of DKD. However, due to the rising number of patients with DKD worldwide, and based on the findings in the present study, SWE appears to be a simple, practical, and “virtual” method for evaluating the native kidney in patients with advanced DKD. Additionally, the findings in the present study suggest that SWE may be applied for evaluation of chronic morphological changes in DKD patients with a single kidney and those on anticoagulant therapy. However, this technology is a new tool for renal tissue characterization and further studies are needed to provide additional confirmation and validation in clinical practice.

Limitations
The present study was performed in one center and included a relatively small number of patients. The study was also limited because of the absence of real-time renal histopathologic samples of the studied population, which were not obtained due to ethical considerations. The maximum detection depth of only 8 cm limits the use of the SWE method, and the accuracy of measurements depends on the skill of the examiner.

Conclusion
In patients with advanced DKD, SWE imaging may be utilized as a simple and practical method for quantitative evaluation of the chronic morphological changes and for the differentiation between different CKD grades. Multicenter studies are needed to provide additional confirmation and validation in clinical practice.

Disclosure
The authors report no conflicts of interest in this work.

References


